Published Date: 13 Mar 2023
Pregnant women's use of asthma medications is not associated with an increased risk of autism, ADHD or Tourette's syndrome, a new study has found.
Read Full NewsAnemia Correction Before Colorectal Surgery Yields No Postoperative Gains
Mease discussed his hopes for the new approval's impact on the fibromyalgia field.
The rheumatology month in review emphasizes new approvals and the latest comparative research.
Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.
Q3 2025 saw a number of exciting approvals and data on promising therapies in development.
Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.
Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.
1.
Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.
2.
Brain cancer: a Q&A session.
3.
Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma
4.
Daily physical activity, even at light intensities, linked to lower cancer risk
5.
Hit and Miss for CDK4/6 Inhibitor in Recurrent Brain Cancer
1.
A Revolutionary Guide to Calculating Absolute Neutrophil Counts
2.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
3.
Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective
4.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
5.
Synovial Sarcoma of Female Urethra: Case Report and Literature Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
3.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation